Table 1.
Baseline no RVD | Baseline RVD | p-value | |||
---|---|---|---|---|---|
No RVD (n = 325) | New-onset RVD (n = 106) | Normalized RVD (n = 73) | Residual RVD (n = 94) | All groups | |
Age, years | 72.0 (65.0–77.0) | 72.5 (67.0–79.0) | 71.0 (66.0–80.0) | 73.0 (66.0–80.0) | 0.256 |
Female | 30.2 (98) | 20.8 (22) | 15.1 (11) | 19.1 (18) | 0 . 011 |
Body mass index, kg/m2 | 23.4 (20.3–26.6) | 22.1 (19.9–24.7) | 22.0 (19.6–24.6) | 22.3 (19.0–24.7) | <0.001 |
Body surface area, m2 | 1.6 (1.3–1.8) | 1.5 (1.3–1.7) | 1.5 (1.4–1.6) | 1.6 (1.3–1.7) | 0.059 |
NYHA functional class III or IV | 95.4 (310) | 98.1 (104) | 98.6 (72) | 98.9 (93) | 0.262 |
Diabetes mellitus | 20.9 (68) | 18.9 (20) | 24.7 (18) | 36.2 (34) | 0.012 |
Hypertension | 60.0 (195) | 67.0 (71) | 68.5 (50) | 79.8 (75) | 0.004 |
Hypercholesterolaemia | 24.3 (79) | 25.5 (27) | 27.4 (20) | 39.4 (37) | 0.036 |
Coronary artery disease | 28.3 (92) | 30.2 (32) | 26.0 (19) | 42.6 (40) | 0.050 |
Percutaneous coronary intervention | 3.1 (10) | 2.8 (3) | 5.5 (4) | 5.3 (5) | 0.525 |
Coronary artery bypass surgery | 3.4 (11) | 1.9 (2) | 4.1 (3) | 5.3 (5) | 0585 |
Stroke or TIA | 3.4 (11) | 3.8 (4) | 5.5 (4) | 2.1 (2) | 0.681 |
Peripheral vascular disease | 40.3 (131) | 38.7 (41) | 41.1 (30) | 43.6 (41) | 0.911 |
Chronic obstructive pulmonary disease | 8.0 (26) | 8.5 (9) | 13.7 (10) | 14.9 (14) | 0.146 |
Dialysis | 23.7 (77) | 17.9 (19) | 21.9 (16) | 23.4 (22) | 0.660 |
Atrial fibrillation | 20.9 (68) | 26.4 (28) | 24.7 (18) | 28.7 (27) | 0.366 |
Permanent pacemaker implant | 3.4 (11) | 5.7 (6) | 1.4 (1) | 6.4 (6) | 0.289 |
STS score,% | 6.7 (3.2–9.0) | 6.2 (4.7–7.9) | 7.1 (5.5–8.3) | 7.7 (5.9–9.1) | 0.083 |
EuroSCORE II,% | 6.0 (2.9–8.5) | 6.2 (4.0–7.8) | 6.2 (5.5–7.9) | 7.4 (6.0–8.6) | 0.021 |
EuroSCORE II, European system for cardiac operative risk evaluation II; NYHA, New York Heart Association; RVD, right ventricular dysfunction; STS, society of thoracic surgeons; TIA, transient ischemic attack.
The bold p value means that the value is <0.05.